New Drug Applications

 

New Drug Applications - Overview

The New Drug Application (NDA) is submitted to the United States Food and Drug Administration (US FDA) for approval of a new drug through the 505(b)(1) and 505(b)(2) NDA Regulatory pathways. Most sponsors find NDA submissions challenging as they must identify the right pathways for their drug development case and define the appropriate Regulatory strategy for the NDA filing process. Moreover, if the information in the NDA submission is inadequate, the US FDA may Refuse-to-File (RTF) the NDA, due to which the sponsor cannot move forward unless additional information is submitted to comply with the Agency’s requirements. Knowledge of the guidance detailing the reasons for an RTF of a new drug application and its review process will save the investment (agency fee) and time for sponsors during the NDA filing process.

Freyr assists sponsors with end-to-end Regulatory support for their NDA submission process, starting from the pre-NDA meetings to the submission of NDA annual reports and lifecycle management of the product.

New Drug Applications - Expertise

  • Expert advice on availing agency support via expedited programs (i.e., Fast Track designation, Breakthrough Therapy designation, Accelerated Approval process, and Priority Review designation).
  • Extensive understanding of the Federal regulations and submission pathways (505(b)(1), 505(b)(2) and 505 (j)), data requirements for New Drug Application (NDA) preparation, and significant experience in NDA filings and NDA review process.
  • Pre-submission meeting support, including briefing, package preparation, and meeting representation to discuss scientific issues with the US FDA.
  • Strategic support in identifying the optimal Regulatory pathway for the NDA submission.
  • Regulatory support for pre- and post-submission interactions and follow-up activities with the US FDA throughout the NDA approval program.
  • Post-approval NDA lifecycle management (Supplements, CBE 30, CBE, Annual Reports, etc.).
  • Strategy and submission support in managing Complete Response Letters (CRLs) for NDA registration.
  • NDA templates, with technical information for NDA preparation and eCTD submissions.
  • Regulatory response strategy, preparation, and on-time response submission to the US FDA queries/information requests.
  • Gap analysis of developmental data/source data against NDA submission/NDA registration requirements and offering guidance to sponsors for designing a risk mitigation plan for the identified Regulatory gaps.
  • Compilation and technical review of 505(b)(1) and 505(b)(2) NDA packages (including preparation of Module 1 documents and other NDA registration forms), publishing, and submission of the application in the eCTD format via the FDA ESG.
New Drug Applications

Celebrating Customers Success

 

Medicinal Products

Regulatory Affairs

India

Thank you for the timely support over the weekend, which allowed us to resubmit quickly after being notified. This continuously demonstrates Freyr's commitment towards our company’s milestones.

Director - Global Regulatory Affairs – Operations

India-based, Global Top Generic Pharma Company

 

Medicinal Products

Publishing

UK

I am sure you have heard by now that we have received our first-ever approval from the FDA for our Brands division. This is a major milestone for us as well as for my team here in Reg Ops. I would be remiss if I didn’t point out that we would not have been able to do this without the help of your dedicated team. From the original filing, then the following year of responses, all helped get us to final approval.

Thank you Freyr team for a job well done!

Sr. Director, Head of Regulatory Operations

Ireland-based, Global Specialty Pharmaceutical Company

 

Medicinal Products

Regulatory Affairs

USA

Please relate to the team the excellent job they have done on the IND reactivation. Specifically, the high-quality module 3, written by Freyr. It was very comprehensive, very few revisions were required, and we had no questions from Health Canada or FDA. No CMC questions: that was a first for me. So very responsive to my many requests, which I am sure can be frustrating but always helpful while producing excellent work.

Thank you for always being available and responding quickly and comprehensively to all my requests.

What a great team you have, Freyr.

Lynne McGrath

Regulatory Consultant

 

Medicinal Products

Regulatory Affairs

USA

Congratulations!!! ​

Thanks for your great support for a successful ANDA filing, especially to the publishing team. Heartfully appreciate their last hours of hard work.

Assistant Manager​

US-based, Leading, Complex Generic Pharmaceutical Products Company​

 

Medicinal Products

Regulatory Affairs

USA

Thank you all for the great support!​

CEO

US-based, Leading Innovative Pharmaceuticals Company​

 

Medicinal Products

Regulatory Affairs

USA

The ANDA receipt has been received! Thank you very much for your hard work, patience, and support for our work over the last couple of months. We are delighted that we were able to meet the timeline and hit an important corporate goal of our young company. ​

Thank you again, and we look forward to working with your team on the next project!

Senior Director of Business and Product Development​

US-based, Leading Innovator Pharmaceuticals Company​